The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
With the continuous improvement of human technology, the medical field has gradually moved from molecular therapy to cellular therapy. As a safe and effective therapeutic tool, cell therapy has successfully created a research boom in the modern medical field. Mesenchymal stem cells (MSCs) are derived from early mesoderm and have high self-renewal and multidirectional differentiation ability, and have become one of the important cores of cell therapy research by virtue of their immunomodulatory and tissue repair capabilities. In recent years, the application of MSCs in various diseases has received widespread attention, but there are still various problems in the treatment of MSCs, among which the heterogeneity of MSCs may be one of the causes of the problem. In this paper, we review the correlation of MSCs heterogeneity to provide a basis for further reduction of MSCs heterogeneity and standardization of MSCs and hope to provide a reference for cell therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
A perivascular origin for mesenchymal stem cells in multiple human organs
Crisan, M., Yap, S., Casteilla, L., Chen, C.-W., Corselli, M., Park, T. S., Andriolo, G., Sun, B., Zheng, B., Zhang, L., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.07.003 · Cited by 3,991 · cited 1×
“…MSCs has been obtained from in vitro culture, which led to a long period of time where the non-expression of CD34 was used as a criterion for MSCs, but as research progressed it was gradually recognized that CD34 may be expressed in vivo but rapidly downregulated during in vitro culture [119–121].”
Self-citationKern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0342 · Cited by 3,370 · cited 1×
“It has been shown that human umbilical cord perivascular cells (HUCPVCs) show a higher proliferative potential than BM-MSCs and are able to differentiate into bone, cartilage, and adipose, and in addition, HUCPVCs exhibit higher levels of CD146 relative to BM-MSCs [78].”
BackgroundMesenchymal stem cells as trophic mediators
Caplan, A. I., & Dennis, J. E. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20886 · Cited by 2,992
Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases
Shi, Y., Wang, Y., Li, Q., Liu, K., Hou, J., Shao, C., & Wang, Y. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0023-5 · Cited by 1,223 · cited 1×
“For example, in an inflammatory environment MSCs may express more major histocompatibility complex (MHC) class II, which can affect the function of MSCs in immunomodulatory and anti-inflammatory actions [125, 126].”
BackgroundXu, M., Tchkonia, T., Ding, H., Ogrodnik, M., Lubbers, E. R., Pirtskhalava, T., White, T. A., Johnson, K. O., Stout, M. B., Mezera, V., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515386112 · Cited by 915 · cited 1×
“In particular, through senescence-associated secretory phenotype (SASP), aging cells themselves produce many pro-inflammatory cytokines and chemokines [49, 50].”
BackgroundViswanathan, S., Shi, Y., Galipeau, J., Krampera, M., Leblanc, K., Martin, I., Nolta, J., Phinney, D. G., & Sensebe, L. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.08.002 · Cited by 839
Targeting senescent cells enhances adipogenesis and metabolic function in old age
Xu, M., Palmer, A. K., Ding, H., Weivoda, M. M., Pirtskhalava, T., White, T. A., Sepe, A., Johnson, K. O., Stout, M. B., Giorgadze, N., et al. (2015) · eLife · doi:10.7554/elife.12997 · Cited by 604 · cited 1×
“In particular, through senescence-associated secretory phenotype (SASP), aging cells themselves produce many pro-inflammatory cytokines and chemokines [49, 50].”
BackgroundAdipose-derived and bone marrow mesenchymal stem cells: A donor-matched comparison
Mohamed-Ahmed, S., Fristad, I., Lie, S. A., Suliman, S., Mustafa, K., Vindenes, H., & Idris, S. B. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0914-1 · Cited by 515 · cited 1×
“This can result in inconsistent growth rates and differentiation levels among different MSCs during the treatment process, thereby affecting the treatment outcome [129].”
BackgroundSiegel, G., Kluba, T., Hermanutz-Klein, U., Bieback, K., Northoff, H., & Schäfer, R. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-146 · Cited by 493
Cited by
Mesenchymal stromal cells as cancer promoters
Antoon, R., Overdevest, N., Saleh, A. H., & Keating, A. (2024) · Oncogene · doi:10.1038/s41388-024-03183-1 · Cited by 75
Kannan, S., Gokul Krishna, S., Gupta, P. K., & Kolkundkar, U. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-62544-8 · Cited by 39
Kukaj, D., Niebert, S., Biehl, C., Reichart, U., Schueler, C., & Burk, J. (2025) · Regenerative Therapy · doi:10.1016/j.reth.2025.09.012 · Cited by 5
“MSC heterogeneity, including donor-specific effects and the loss of potency during in vitro expansion, can impact therapeutic outcomes [21,34,35].”
Metadata
- Authors
- Li, J., Wu, Z., Zhao, L., Liu, Y., Su, Y., Gong, X., Liu, F., & Zhang, L.
- Venue
- Stem Cell Research & Therapy
- Published
- 2023-12-20
- Volume
- 14
- Issue
- 1
- Pages
- 381-381
- ISSN
- 1757-6512 (ISSN-L)
- OpenAlex
- W4389991843
- Cited by
- 150
- References
- 20
- FWCI
- 21.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy. https://app.cochat.ai/papers/10.1186/s13287-023-03587-y
- The paper
- Li, J., Wu, Z., Zhao, L., Liu, Y., Su, Y., Gong, X., Liu, F., & Zhang, L. (2023). The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-023-03587-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.